Floatz logo

Mitoxantrone

Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)

Alice MimsSmall moleculePhase 2Dormant
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) cohort.

Asset / SponsorPhaseRating
Daunorubicin
National Cancer Institute (NCI)
Phase 3BBB
Cytosin-Arabinosid
Alice Mims
Phase 3BBB
Fludarabine
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2BBB
Idarubicine
Bruno C. Medeiros
Phase 2BBB
ETOPOSIDE
Alice Mims
Phase 3BBB

View all 50 →

Same molecule, other indications

Mitoxantrone is also rated in:

acute promyelocytic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
74 / 100
View asset →
myeloid neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →